William Blair Has Positive Estimate for DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Dynavax Technologies in a report issued on Monday, January 13th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.16 per share for the year, up from their prior estimate of $0.15. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share.

Other research analysts also recently issued reports about the company. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday. HC Wainwright boosted their price target on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.48 on Wednesday. The company has a market cap of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. The stock has a fifty day moving average price of $12.77 and a 200 day moving average price of $11.66. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $14.41.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB boosted its position in Dynavax Technologies by 42.7% during the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after acquiring an additional 232,690 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Dynavax Technologies by 55.1% in the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 1,457 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Dynavax Technologies by 5.7% in the third quarter. Franklin Resources Inc. now owns 82,415 shares of the biopharmaceutical company’s stock valued at $862,000 after buying an additional 4,459 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Dynavax Technologies in the third quarter valued at $89,000. Finally, Sanctuary Advisors LLC lifted its holdings in shares of Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 1,484 shares during the period. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.